Loading…
Nektar Therapeutics is projected to rise to $91.77 by 2027, a +28% move from its current price of $71.45. NKTR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $69.58 | $71.48 | $73.44 | +0.05% |
| Aug 2 | $68.84 | $71.52 | $74.30 | +0.09% |
| Aug 3 | $68.28 | $71.55 | $74.97 | +0.14% |
| Aug 4 | $67.82 | $71.58 | $75.55 | +0.18% |
| Aug 5 | $67.42 | $71.61 | $76.07 | +0.23% |
| Aug 6 | $67.06 | $71.65 | $76.55 | +0.27% |
| Aug 7 | $66.73 | $71.68 | $76.99 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $66.73 | $71.68 | $76.99 | +0.32% |
| Week 2 | $65.00 | $71.91 | $79.55 | +0.64% |
| Week 3 | $63.74 | $72.14 | $81.64 | +0.96% |
| Week 4 | $62.73 | $72.37 | $83.48 | +1.28% |
| Week 5 | $61.88 | $72.60 | $85.17 | +1.61% |
| Week 6 | $61.13 | $72.83 | $86.76 | +1.93% |
| Week 7 | $60.48 | $73.06 | $88.27 | +2.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large B-cell lymphoma.
The company was incorporated in 1990 and is headquartered in San Francisco, California. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA.
The current price is $70.73. The stock has a market cap of $2.39B and is ranked 1791.
The near-term forecast indicates the 2026 average price at $70.73 with a Neutral sentiment, followed by bullish potential in 2027 and beyond (avg values from $91.38 in 2027 to $114.34 in 2030 and higher).
From 2027 onward, the forecast shows strong upside: 2027 avg $91.38; 2028 avg $102.34; 2029 avg $103.77; 2030 avg $114.34; 2031 $118.42; 2032 $133.19; 2033 $178.85; 2034 $186.14; 2035 $186.90; 2040 $290.85; 2050 $517.08.
A major floor 22.9% below — a decisive break under it would weaken the trend.
The nearest floor, 14.7% below — buyers have tended to step in here.
The nearest ceiling, 4.8% above — a clean break opens room to run.
A major ceiling 40.4% above — clearing it would confirm fresh momentum.
Key NKTR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NKTR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $71.00 | Buy | $70.74 | Buy |
| MA 10 | $69.54 | Buy | $70.09 | Buy |
| MA 20 | $70.03 | Buy | $69.16 | Buy |
| MA 50 | $65.72 | Buy | $68.67 | Buy |
| MA 100 | $72.23 | Sell | $67.59 | Buy |
| MA 200 | $62.96 | Buy | $61.01 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.59 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 50.05 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.20 | Buy |
| ROC (12) | 6.37 | Buy |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.23 | Buy |
| Awesome (5,34) | 3.79 | Buy |
| Ultimate (7,14,28) | 71.41 | Sell |
| Momentum (10) | 4.40 | Buy |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 71.66 | Sell |
| ADX (14) | 12.59 | Neutral |
| ATR (14) | 1.56 | Info |
Technical sentiment is BULLISH. RSI(14) is 50, with SMA50 at $65.98 and SMA200 at $62.61.
Support is at $56.78 and resistance at $74.90. The 30-day range runs from $57.63 to $86.80, and annualized volatility is 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $35.12 | $71.45 | $97.87 | 0% | Neutral | |
| $73.26 | $91.77 | $121.51 | +28% | Bullish | |
| $80.77 | $104.05 | $142.98 | +46% | Bullish | |
| $80.96 | $106.72 | $150.97 | +49% | Bullish | |
| $88.45 | $118.99 | $172.46 | +67% | Bullish | |
| $91.80 | $125.79 | $186.23 | +76% | Bullish | |
| $100.86 | $140.59 | $212.12 | +97% | Bullish | |
| $130.66 | $185.08 | $284.09 | +159% | Bullish | |
| $136.12 | $195.78 | $305.31 | +174% | Bullish | |
| $135.47 | $197.71 | $312.87 | +177% | Bullish | |
| $200.08 | $311.98 | $524.98 | +337% | Bullish | |
| $322.17 | $562.83 | $1,035.71 | +688% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $35.12 | $71.45 | $83.33 | +0.00% |
| August 2026 | $61.06 | $71.65 | $86.02 | +0.28% |
| September 2026 | $62.95 | $74.48 | $90.61 | +3.95% |
| October 2026 | $65.55 | $78.07 | $95.98 | +4.82% |
| November 2026 | $65.35 | $78.26 | $97.02 | +0.24% |
| December 2026 | $65.10 | $78.34 | $97.87 | +0.11% |
Click any year to see its month-by-month NKTR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The NKTR price prediction for 2026 points to an average of $71.45 (low $35.12, high $97.87) — a potential gain of 0% on today's $71.45. Price action looks broadly range-bound.
In 2027, NKTR is projected to trade between $73.26 and $121.51, averaging $91.77 — a potential gain of +28% from today's $71.45. That is up +28% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Nektar Therapeutics's 2028 outlook centres on $104.05, within a $80.77 to $142.98 range. That is up +13% on the projected 2027 average. That marks a +46% change versus current levels. Momentum favours further upside here.
By 2029, NKTR could reach as high as $150.97, with a base case around $106.72 and support toward $80.96 — roughly +49% from $71.45. Buyers look set to stay in control over this stretch.
Expect NKTR to range from $88.45 to $172.46 through 2030. The $118.99 average target implies a +67% move from current prices. That is up +11% on the projected 2029 average. Momentum favours further upside here.
The NKTR price prediction for 2031 points to an average of $125.79 (low $91.80, high $186.23) — a potential gain of +76% on today's $71.45. Buyers look set to stay in control over this stretch.
In 2032, NKTR is projected to trade between $100.86 and $212.12, averaging $140.59 — a potential gain of +97% from today's $71.45. That is up +12% on the projected 2031 average. Momentum favours further upside here.
Nektar Therapeutics's 2033 outlook centres on $185.08, within a $130.66 to $284.09 range. That is up +32% on the projected 2032 average. That marks a +159% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, NKTR could reach as high as $305.31, with a base case around $195.78 and support toward $136.12 — roughly +174% from $71.45. Momentum favours further upside here.
Expect NKTR to range from $135.47 to $312.87 through 2035. The $197.71 average target implies a +177% move from current prices. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The NKTR price prediction for 2040 points to an average of $311.98 (low $200.08, high $524.98) — a potential gain of +337% on today's $71.45. Momentum favours further upside here.
In 2050, NKTR is projected to trade between $322.17 and $1,035.71, averaging $562.83 — a potential gain of +688% from today's $71.45. That is up +80% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NKTR today (≈ 13.995801 NKTR) could be worth
$7,877.19
+$6,877.19 (+688%) by 2050 · US Dollar
Based on the average projected NKTR price of $562.83 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NKTRwould be worth at today's price.
$1,000 invested in NKTR on Jul 30, 2025 (≈ 45.310377 NKTR) would be worth
$3,237.43
+$2,237.43 (+223.7%) today · 3.24× · US Dollar
Based on a NKTR entry price of $22.07 vs. today's $71.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $69.36 | $1,030.13 | +3.0% |
| 1 month ago | $69.81 | $1,023.49 | +2.3% |
| 3 months ago | $86.46 | $826.39 | -17.4% |
| 6 months ago | $37.33 | $1,914.01 | +91.4% |
| 1 year ago | $22.07 | $3,237.43 | +223.7% |
| All time (5.0y) ago | $239.4 | $298.45 | -70.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NKTR forecast.
Our base-case forecast reaches $140.00 around 2032.
Implied market cap at $140.00: $4.73B
The multi-year forecast shows a path of rising averages from 2026 to 2050. The 2026 average is $70.73 (min $35.12, max $98.90) with a Neutral sentiment, expanding to a 2027 average of $91.38 and a bullish trajectory through the 2030s.
Key milestones include 2030 average of $114.34 with ROI 61.7%, 2040 average of $290.85 with ROI 311.3%, and 2050 average of $517.08 with ROI 631.1%. The sentiment remains bullish in these years, with progressively higher ranges projected over time. These are estimates, not guarantees, and market conditions can change.
Tap a question to reveal the answer.
Avg $114.34; min $82.80; max $170.77; ROI 61.7%; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward and rising averages, with an average of $114.34 in 2030, $290.85 in 2040, and $517.08 in 2050, with a max of $1,004.46. These are estimates, not guarantees.
Yes—the forecast max reaches $208.01 in 2032 and $284.67 in 2033, with higher max values later.
Min $35.12; Avg $70.73; Max $98.90; Sentiment Neutral.
Avg $517.08; Min $272.83; Max $1,004.46; ROI 631.1%; Sentiment BULLISH.
Nektar Therapeutics Community Discussion
0Share your Nektar Therapeutics price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.